$0.00
Shopping Cart
Facebook-f Instagram
Donate

Clinical Trial Record

Return to Clinical Trials

A Beta-only IL-2 ImmunoTherapY Study

2021-08-27

2026-06-30

2026-12-30

115

Study Overview

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

The study drug, MDNA11, long-acting ⊾ta-only" recombinant interleukin-2 (rIL-2). MDNA11 specifically engineered to overcome the shortcomings of rhIL-2 (aldesleukin) by preferentially activating immune effector cells (CD8+ T- and NK cells) responsible for killing cancer cells, with minimal or no stimulation of immunosuppressive Tregs. It is designed to potentially enhance host immune response and fusion to albumin increases the half-life further avoiding frequent dosing required with rhIL-2. The study will be conducted at up to 30 clinical sites following regulatory authority and institutional review board / independent ethics committee (IRB/ IEC) approval and completion of informed consent. The study will be conducted in multiple parts: * Monotherapy (MDNA11 alone) dose escalation * Monotherapy (MDNA11 alone) dose expansion in select tumor types * Combination (MDNA11 + pembrolizumab) dose escalation * Combination (MDNA11 + pembrolizumab) dose expansion in select tumor types Approximately 115 patients will be enrolled. After commencing treatment (first exposure of MDNA11 alone or MDNA11 + pembrolizumab), tumor assessment by CT/MRI will be performed every 8 weeks ± 1 week until immune confirmed progressive disease ("iCPD") by iRECIST, discontinuation of study drug(s), withdrawal of consent or loss to follow-up. Treatment beyond progression may be permitted if criteria are met. Patients can withdraw from participation at any time.

  • Advanced Solid Tumor
  • Unresectable Solid Tumor
  • Clear Cell Renal Cell Carcinoma
  • Triple Negative Breast Cancer
  • Non-Small Cell Lung Cancer Squamous
  • Non-Small Cell Lung Cancer Non-squamous
  • Colorectal Cancer (MSI-H)
  • Gastric Cancer
  • Cervical Cancer
  • Basal Cell Carcinoma
  • Bladder Cancer
  • Merkel Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
  • Cutaneous Squamous Cell Carcinoma
  • Pleural Mesothelioma
  • Esophageal Cancer
  • Endometrial Carcinoma
  • Solid Tumor
  • Solid Tumor, Adult
  • MSI-H Solid Malignant Tumor
  • Cancer With A High Tumor Mutational Burden
  • Epithelial Ovarian Carcinoma
  • Primary Peritoneal Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • Acral Melanoma
  • Mucosal Melanoma
  • Cutaneous Melanoma
  • DMMR Solid Malignant Tumor
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • MSI-H Cancer
  • DMMR Cancer
  • Pancreas Adenocarcinoma (MSI-H)
  • Skin Cancer
  • DRUG: MDNA11
  • DRUG: Pembrolizumab (KEYTRUDA®)
  • MDNA11-01
  • KEYNOTE-E53 (OTHER Identifier) (OTHER: Merck Sharp & Dohme, LLC)
  • MK3475-E53 (OTHER Identifier) (OTHER: Merck Sharp & Dohme, LLC)
  • 2023-507536-21-00 (CTIS Identifier) (CTIS: )

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2021-09-10  

N/A  

2024-08-26  

2021-10-07  

N/A  

2024-08-27  

2021-10-21  

N/A  

2024-08  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Sequential

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: MDNA11

MDNA11 is a long-acting "beta-only" recombinant interleukin-2 (rIL-2) albumin fusion

DRUG: MDNA11

  • MDNA11 will be administered, IV on a once every 2 weeks (Q2W) dosing schedule. Provisional dose cohorts for monotherapy dose escalation doses ranging from 0.003 to 0.6 (mg/kg): until determining the monotherapy Recommended Dose for Expansion (mRDE).

DRUG: Pembrolizumab (KEYTRUDA®)

  • MDNA11 will be administered in combination with pembrolizumab, IV. MDNA11 dose range to be evaluated in combination with pembrolizumab until determining the combination Recommended Dose for Expansion (cRDE).
Primary Outcome MeasuresMeasure DescriptionTime Frame
MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE)Evaluation of tolerability as measured by number of patients with dose limiting toxicities (DLTs)24 months
Incidence of Treatment Related Adverse Events (TRAEs)Rate of TRAEs in patients with advanced solid tumors24 months
Incidence of Treatment Emergent Adverse Events (TEAEs)Rate of TEAEs in patients with advanced solid tumors24 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Pharmacokinetic characteristics on MDNA11 - Cmax (ug/mL)Maximum observed serum drug concentrationUp to 24 months
Pharmacokinetic characteristics on MDNA11 - Tmax (h)Time to maximum observed serum drug concentrationUp to 24 months
Pharmacokinetic characteristics on MDNA11 - AUClast (h.ug/mL)Area under the serum concentration vs time curve from time zero to the last measurable concentrationUp to 24 months
Immunogenicity of MDNA11 (anti-drug antibodies)Incidence and persistence of anti-drug antibodies to MDNA11Up to 24 months
Pharmacodynamic effects of MDNA11Measurement of translational parameters - Flow cytometry analysis of immune cells in blood and serum measurements of cytokine levelsUp to 24 months
Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Overall Response Rate (ORR)Assessed by RECIST v1.1 and iRECIST; CR+PR/Evaluable NApproximately 24 months
Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Disease Control Rate (DCR)CR+PR+SD/Evaluable NApproximately 24 months
Anti-tumor activity of MDNA11 (alone or in combination with CPI) - Progression Free Survival (PFS)Time from signing ICF to disease progressionApproximately 24 months

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Nina Merchant

Phone Number: 604-340-3081

Email: nmerchant@medicenna.com

Study Contact Backup

Name: Melissa Coello

Phone Number: 267-476-2313

Email: mcoello@medicenna.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Key Inclusion Criteria:
    1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. 3. Must be able and willing to provide written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures. 4. Histologically or cytologically confirmed locally advanced or metastatic solid tumor (see tumor types listed under conditions) 5. Demonstrated adequate organ function 6. Measurable disease as per Response Evaluation Criteria in Solid Tumors, (RECIST v1.1) and documented by CT and/or MRI. 7. Life expectancy of ≥ 12 weeks. 8. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and within 72 hours before the first dose of study drug(s). Women must not be breastfeeding. 9. Agree to use highly effective contraception methods. WOCBP must agree to use highly effective birth control.
    Key Exclusion Criteria:
    1. Last administration of prior antitumor therapy:

  • Prior systemic anti-cancer therapy including investigational agents within 4 weeks (could consider shorter interval for kinase inhibitors or other short half-life drugs) prior to start of treatment.
  • Prior radiotherapy within 2 weeks prior to start of treatment or has had a history of radiation pneumonitis. A 1-week washout is required for palliative radiation (<2 weeks of radiotherapy) to non-CNS disease.
  • Radiation therapy to the lung that is > 30Gy within 6 months prior to start of treatment.
  • Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to start of treatment. Concomitant participation in an observational study must be discussed on a case-by-case basis with the MM for approval. 2. Has known active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to start of treatment, subject to discussion with MM. 3. Active malignancy (other than the disease under treatment in the study) within the previous 3 years except for curable cancers. 4. Condition requiring long-term systemic treatment with either corticosteroids > 10 mg daily prednisone equivalent or any other form of immunosuppressive therapy within 7 days prior to start of treatment. 5. Clinically significant active, known or suspected autoimmune disease, or diseases that can be exacerbated with immunotherapy. 6. Severe pulmonary, cardiac or other systemic disease. 7. Known hepatitis B or C virus infection. 8. Females who are pregnant or lactating or planning to become pregnant during the study. 9. Has had an allogeneic tissue/solid organ transplant. 10. Active infection requiring systemic therapy. 11. Any medical, emotional or psychiatric condition that interfere with the patient's ability to adhere to the protocol 12. Any other underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug(s) unsafe or obscure the interpretation of toxicity determination or adverse events. 13. Known severe hypersensitivity to any component of study drug(s). 14. Inability to comply with study and follow up procedures as judged by the Investigator.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • Merck Sharp & Dohme LLC
  • STUDY_DIRECTOR: Nina Merchant, Medicenna Therapeutics

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Treat yourself

Let Us Take Care Of You

BOOK AN APPOINTMENT ⟶
footer logo

About

Events

Fundraising

Contact Us

Facebook-f Instagram

NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved

Make-A-Will Month

Snag 6508be92
Learn More
Donate Now Online
Other Ways to Donate